Literature DB >> 17100128

[Optimisation of the antibiotic policy in the Netherlands. X. The SWAB guideline for antimicrobial treatment of complicated urinary tract infections].

S E Geerlings1, P J van den Broek, E P van Haarst, L J Vleming, K M A van Haaren, R Janknegt, G J Platenkamp, J M Prins.   

Abstract

The 'Stichting Werkgroep Antibioticabeleid' (SWAB; Dutch Working Party on Antibiotic Policy) has developed an evidence-based guideline for the empirical antimicrobial treatment of complicated urinary tract infections (UTIs) in hospitalised adult patients. The choice of treatment is based on recent Dutch data on the resistance ofuropathogens to the most frequently used antibiotics. The first choice for empirical antibiotic treatment in a patient with a complicated UTI is a 2nd or 3rd generation cephalosporin or the combination of amoxicillin and gentamicin. Amoxicillin-clavulanic-acid intravenously is the second empirical choice. The treatment duration must be at least 10 days. The treatment must be adjusted after the results of the urine culture become known and made more specific if possible. Oral treatment can be given if the patient's clinical situation allows it. There are separate recommendations for the treatment ofUTIs in the following patient categories: men, pregnant women, patients with a urinary catheter, patients with diabetes mellitus and patients with renal diseases, congenital polycystic kidney disease or pyocystis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100128

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  6 in total

1.  Adequacy of an evidence-based treatment guideline for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence.

Authors:  V Spoorenberg; J M Prins; E E Stobberingh; M E J L Hulscher; S E Geerlings
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

2.  Recommendations for the empirical treatment of complicated urinary tract infections using surveillance data on antimicrobial resistance in the Netherlands.

Authors:  Maike Koningstein; Akke K van der Bij; Marlieke E A de Kraker; Jos C Monen; Jan Muilwijk; Sabine C de Greeff; Suzanne E Geerlings; Maurine A Leverstein-van Hall; Maurine A Leverstein- van Hall
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

3.  Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine.

Authors:  Christina F M van der Donk; Jeroen H B van de Bovenkamp; Els I G B De Brauwer; Patrick De Mol; Karl-Heinz Feldhoff; Wiltrud M Kalka-Moll; Sita Nys; Inge Thoelen; Thera A M Trienekens; Ellen E Stobberingh
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

4.  Usability application of multiplex polymerase chain reaction in the diagnosis of microorganisms isolated from urine of patients treated in cancer hospital.

Authors:  Zefiryn Cybulski; Katarzyna Schmidt; Alicja Grabiec; Zofia Talaga; Piotr Bociąg; Jacek Wojciechowicz; Andrzej Roszak; Witold Kycler
Journal:  Radiol Oncol       Date:  2013-07-30       Impact factor: 2.991

5.  Appropriate antibiotic use for patients with complicated urinary tract infections in 38 Dutch Hospital Departments: a retrospective study of variation and determinants.

Authors:  V Spoorenberg; S E Geerlings; R B Geskus; T M de Reijke; J M Prins; M E J L Hulscher
Journal:  BMC Infect Dis       Date:  2015-11-09       Impact factor: 3.090

6.  A Cluster-Randomized Trial of Two Strategies to Improve Antibiotic Use for Patients with a Complicated Urinary Tract Infection.

Authors:  Veroniek Spoorenberg; Marlies E J L Hulscher; Ronald B Geskus; Theo M de Reijke; Brent C Opmeer; Jan M Prins; Suzanne E Geerlings
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.